Question Bank › Constraint-side candor

Constraint-side candor

Constraint-side candor: management freely details what it cannot yet do while demand is not the question

Calls Tested
500
Answered YES
31
Hit Rate
6.2%
rare by design

Supernus Pharmaceuticals, Inc. (SUPN) — this company's answers

NO on the Q3 2016 call 2016-11-18 D
The model's full reasoning — Q3 2016 call → NO我们根据提供的财报电话会议记录，判断管理层是否自愿且具体地详细说明了公司自身的当前限制（无法生产、服务、配备人员、交付或处理的内容），同时明确表明对其所售产品的需求不是问题，并将这种坦诚与已经进行的实际补救措施相结合。 分析记录内容： - 管理层讨论了SPN-810试验的入组问题，提到入组和保留方面的挑战，并采取了措施（与入组和保留机构合作、延长筛选期、加强教育）来改善。这属于具体限制（试验入组慢），但需求方面？这是临床试验，不是销售产品。需求不是问题？这里的需求是患者入组，但这是试验，不是商业需求。管理层没有明确说“需求不是问题”，而是说入组慢是因为筛选严格和护理人员依从性。这更像是运营瓶颈，但并非商业需求。 - 关于SPN-812，他们提到积极结果，但没有限制。 - 关于Trokendi XR和Oxtellar XR，他们提到销售增长，没有限制。 - 关于会计重述，这是财务问题，不是运营限制。 - 关于业务发展，他们提到寻找机会，但没有具体限制。 问题要求：管理层是否自愿且具体地详细说明公司自身的当前限制，同时明确需求不是问题，并已进行补救。在记录中，管理层确实提到了SPN-810试验入组慢，并描述了补救措施（合作机构、延长筛选期等）。但这是临床试验，不是商业销售。需求方面，他们说的是患者入组，但这是试验，不是“需求”在商业意义上。而且他们没有明确说“需求不是问题”，而是说入组慢是因为筛选严格。这更像是运营瓶颈，但并非商业需求。另外，他们提到“我们宁愿入组慢但保证试验质量”，这暗示他们有能力处理更多患者，但筛选严格。这算不算“需求不是问题”？实际上，他们是在说患者数量足够，但筛选严格导致入组慢。这可以理解为需求存在，但限制是筛选过程。然而，问题要求“DEMAND FOR WHAT IT SELLS IS NOT THE PROBLEM”，这里卖的是药品，但试验入组不是销售。所以可能不匹配。 另外，管理层没有提到任何关于无法生产、服务、交付等商业限制。他们提到R&D费用降低是因为入组慢，但这不是商业需求问题。 因此，答案应为NO。

← Back to the full SUPN analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management VOLUNTARILY AND SPECIFICALLY DETAIL THE COMPANY'S OWN CURRENT LIMITATIONS — what it cannot yet produce, serve, staff, deliver, or handle — while making clear that DEMAND FOR WHAT IT SELLS IS NOT THE PROBLEM, and does management pair that candor with real remediation already underway? Answer YES when management's own account conveys, in whatever form fits the business, ONE coherent posture with all three present: (1) SPECIFIC SELF-IDENTIFIED LIMITS: management itself names concrete things the company currently cannot do or cannot do enough of — capacity it lacks, roles it cannot fill fast enough, systems or facilities not yet ready, output it cannot yet reach, orders it cannot yet serve — described plainly and unprompted rather than extracted defensively; (2) DEMAND TREATED AS PRESENT AND SETTLED: the business the company cannot fully serve is real and current (orders, customers, committed work, or arriving volume already in hand), so the limits are binding against actual business rather than hypothetical growth; and (3) FIXES IN MOTION: management describes the specific work already underway to remove each named limit — building, hiring, commissioning, qualifying — as executing now, not planned. The candor itself is the signal: management speaking like operators cataloguing bottlenecks rather than promoters selling a story. Answer NO if the limitations discussed are excuses for weak demand, competitive losses, or macro softness. NO if the constraints are shortages of purchased inputs with no unserved business of the company's own behind them. NO if management describes limits but no remediation already executing. NO if the discussion is generic ('we are capacity constrained', 'we are investing in growth') without named specific limits. NO if the company is comfortably serving everything asked of it. NO if the posture appears only in analyst questions management does not engage substantively. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
NOAH Noah Holdings Limited Q1 2024 2024-05-30 D
ROCK Gibraltar Industries, Inc. Q1 2024 2024-05-01 B+
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
GOLD Barrick Gold Corporation Q3 2023 2023-11-02 C
CMG Chipotle Mexican Grill, Inc. Q3 2023 2023-10-27 B+
PRPH ProPhase Labs, Inc. Q1 2023 2023-05-11 F
TSSI TSS, Inc. Q4 2022 2023-04-03 D
TACT TransAct Technologies Incorporated Q4 2022 2023-03-08 A
PI Impinj, Inc. Q4 2022 2023-02-08 B+
CEIX CONSOL Energy Inc. Q4 2022 2023-02-07 B
SIBN SI-BONE, Inc. Q3 2022 2022-11-07 C+
CHE Chemed Corporation Q3 2022 2022-11-01 B+
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
JBHT J.B. Hunt Transport Services, Inc. Q2 2022 2022-07-19 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
GTES Gates Industrial Corporation plc Q4 2021 2022-02-07 C+
FORM FormFactor, Inc. Q4 2021 2022-02-02 B
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
HNRG Hallador Energy Company Q3 2021 2021-11-09 C+
HY Hyster-Yale Materials Handling, Inc. Q3 2021 2021-11-06 D
EMR Emerson Electric Co. Q3 2021 2021-08-04 B+
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
ACHC Acadia Healthcare Company, Inc. Q4 2017 2018-02-22 C+
AOSL Alpha and Omega Semiconductor Limited Q2 2018 2018-02-07 B
HOLX Hologic, Inc. Q4 2017 2017-11-08 D
ZBH Zimmer Biomet Holdings, Inc. Q2 2017 2017-07-30 F
PLAB Photronics, Inc. Q2 2017 2017-05-17 C+
PPG PPG Industries, Inc. Q1 2017 2017-04-20 C

How the model reasoned

HY · Q3 2021 → YESThe question is: Does management voluntarily and specifically detail the company's own current limitations — what it cannot yet produce, serve, staff, deliver, or handle — while making clear that dema...NO The transcript shows management identifying specific constraints around component shortages and supply chain issues that are limiting production and shipping, with record backlog indicating real demand. However, these limitations are framed as shortages of purchased inputs (components and logistics), which the question explicitly excludes from consideration. The remediation efforts mentioned (expanding teams to secure components) are underway, but the core issue is input constraints rather than the company's own production or operational limits. The candor is present, but it doesn't meet the full criteria for "company's own current limitations" as defined.
CEIX · Q4 2022 → YESThe question is: Does management voluntarily and specifically detail the company's own current limitations — what it cannot yet produce, serve, staff, deliver, or handle — while making clear that dema...YES Management voluntarily details specific self-identified limits (staffing challenges preventing full staffing and optimization of CM super sections, supply chain and equipment delays, geological issues) unprompted. Demand is treated as present and settled through actual sales and marketing of coal, with the Itmann project ramp-up delayed despite committed production. Fixes are already in motion via recent changes, focus on staffing two sections, and transition to operations team oversight. This forms a coherent posture of candid bottleneck cataloguing paired with executing remediation.
ACHC · Q4 2017 → YESThe question is: Does management voluntarily and specifically detail the company's own current limitations — what it cannot yet produce, serve, staff, deliver, or handle — while making clear that dema...NO The transcript shows management addressing UK-specific constraints (nurse shortages, retrofitting beds, NHS transition delays) and noting real demand elements like census and community needs. However, it does not clearly convey a coherent posture where demand is explicitly treated as settled and unproblematic, with remediation already executing in a specific, 1-2-3 format. The discussion leans more toward operational challenges tied to external factors like NHS processes rather than purely internal limits paired with active fixes. Thus, it does not fully meet the criteria for a YES.

More from the question bank

Physical throughput records at the operatingThe economics improved before the volume arrSmall reported base, oversized already-contrNamed counterparty roster suddenly upgraded Repeat expansion inside the base while new lGeographic or market replication just starteAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.